The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)

被引：0

作者：

Chowdhury, S. ^{[1
,2
]}

Abida, W. ^{[3
]}

Arranz Arija, J. ^{[4
]}

Daugaard, G. ^{[5
]}

Fizazi, K. ^{[6
]}

Gez, E. ^{[7
]}

Heidenreich, A. ^{[8
]}

Joly Lobbedez, F. ^{[9
]}

McDermott, R. ^{[10
]}

Merseburger, A. S. ^{[11
]}

Piulats Rodriguez, J. M. ^{[12
]}

Sautois, B. ^{[13
]}

Sridhar, S. ^{[14
]}

Sternberg, C. N. ^{[15
]}

Watkins, S. ^{[16
]}

Simmons, A. ^{[17
]}

Shetty, S. ^{[18
]}

Golsorkhi, A. ^{[19
]}

Ryan, C. J.

Scher, H. ^{[3
,20
]}

机构：

[1] Guys Hosp, Urol Canc, London, England

[2] Sarah Cannon Res Inst, London, England

[3] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol, 1275 York Ave, New York, NY 10021 USA

[4] Hosp Gen Univ Gregorio Maranon, Med Oncol, Madrid, Spain

[5] Copenhagen Univ Hosp, Rigshospitalet, Oncol, Copenhagen, Denmark

[6] Univ Paris, Grp Urogenitol, Villejuif, France

[7] Sourasky Med Ctr, Dept Oncol, Tel Aviv, Israel

[8] Univ Klinikum Koln, Klin Urol, Cologne, Germany

[9] Ctr Francois Baclesse, Med Oncol, Caen, France

[10] Tallaght & St Vincents Univ Hosp & Canc Trials Ir, Genitourinary Oncol, Dublin, Ireland

[11] Lubeck Univ Hosp, Urol Oncol, Lubeck, Germany

[12] Inst Catalan Oncol, Med Oncol, Barcelona, Spain

[13] Univ Hosp Liege, Med Oncol, Liege, Belgium

[14] Princess Margaret Hosp, Med Oncol, Toronto, ON, Canada

[15] San Camillo Forlanini Hosp, Dept Oncol, Rome, Italy

[16] Clovis Oncol Inc, Clin Sci, Boulder, CO USA

[17] Clovis Oncol Inc, Boulder, CO USA

[18] Clovis Oncol Inc, Clin Operat, Boulder, CO USA

[19] Clovis Oncol Inc, Clin Dev, Boulder, CO USA

[20] UCSF Helen Diller Family Comprehens Canc Ctr, Genitourinary Med Oncol, San Francisco, CA USA

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

836TiP

引用

页数：1

共 50 条

[11] Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations
Abida, W.
Bryce, A. H.
Vogelzang, N. J.
Amato, R. J.
Percent, I.
Shapiro, J. D.
McDermott, R.
Hussain, A.
Patnaik, A.
Petrylak, D.
Ryan, C. J.
Stanton, T.
Zhang, J.
Simmons, A. D.
Despain, D.
Collins, M.
Golsorskhi, T.
Scher, H. I.
Chowdhury, S.
ANNALS OF ONCOLOGY, 2018, 29 : 272 - 272
[12] A phase II trial in progress: Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer and a circulating tumor cell homologous recombination deficiency (HRD) phenotype or BRCA defects.
Chowdhury, Simon
Mateo, Joaquin
Gross, Mitchell
Armstrong, Andrew J.
Cruz-Correa, Marcia
Piulats, Josep M.
Blay, Jean-Yves
Rivas, Delcia
Quintero, Luis
Castro, Henry
Nkobena, Andong
Raponi, Mitch
Pelham, Robert
Landers, Mark Andrew
Montgomery, Robert B.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[13] Second-Line Therapy for Patients with metastatic castration-refractory Prostate Cancer (mCRPC) An international, randomized, open-label, Phase 3 Study of the PARP Inhibitor Rucaparib versus Physicians Choice of Treatment for Patients with metastatic castration-resistant Prostate Cancer (mCRPC) associated with homologous Recombination Deficiency (TRITON3) - AP 100/18 of the AUO
Rexer, H.
Graefen, M.
Merseburger, A.
AKTUELLE UROLOGIE, 2019, 50 (05) : 478 - 479
[14] Rucaparib population pharmacokinetics (PPK) and exposure-response (ER) analyses in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in TRITON2
Chowdhury, S.
Patnaik, A.
Campbell, D.
Shapiro, J.
Bryce, A. H.
McDermott, R.
Sautois, B.
Vogelzang, N. J.
Bambury, R.
Voog, E.
Zhang, J.
Green, M.
Beltman, J.
Despain, D.
Simmons, A. D.
Watkins, S. P.
Golsorkhi, A.
Xiao, J.
Abida, W.
ANNALS OF ONCOLOGY, 2020, 31 : S533 - S534
[15] Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound
Roubaud, G.
Ozguroglu, M.
Penel, N.
Matsubara, N.
Mehra, N.
Kolinsky, M. P.
Procopio, G.
Feyerabend, S.
Joung, J. Y.
Gravis, G.
Nishimura, K.
Gedye, C.
Padua, C.
Shore, N.
Thiery-Vuillemin, A.
Gresty, C.
Brickel, N.
Burgents, J.
Allen, A.
Fizazi, K.
ANNALS OF ONCOLOGY, 2020, 31 : S515 - S516
[16] Statin use and outcome in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated in the TROPIC trial
Lorente, D.
De Velasco Oria, G. A.
Carles, J.
Gillessen, S.
Fizazi, K.
Joshua, A.
Eisenberger, M.
Sartor, O.
de Bono, J. S.
ANNALS OF ONCOLOGY, 2018, 29
[17] Real-world effectiveness of PARP inhibitors (PARPi) in metastatic castration-resistant prostate cancer (mCRPC) by genomic homologous recombination repair (HRR) alterations and homologous recombination deficiency signature (HRDsig).
Triner, Daniel
Graf, Ryon
Gjoerup, Ole
Tukachinsky, Hanna
Ross, Jeffrey S.
Cheng, Heather H.
Pritchard, Colin C.
Zurita, Amado J.
Mateo, Joaquin
Cieslik, Marcin
Morgan, Todd Matthew
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 186 - 186
[18] Metronomic Oral Cyclophosphamide in 2 Heavily Pretreated Patients With Metastatic Castration-resistant Prostate Cancer With Homologous Recombination Deficiency (HRD): A Case Report
Ling, Hang Huong
Lin, Yung-Chang
CLINICAL GENITOURINARY CANCER, 2019, 17 (02) : 157 - 160
[19] Genomic characteristics associated with clinical activity of rucaparib in patients (pts) with BRCA1 or BRCA2 (BRCA)-mutated metastatic castration-resistant prostate cancer (mCRPC)
Abida, Wassim
Campbell, David
Patnaik, Akash
Sautois, Brieuc
Shapiro, Jeremy David
Vogelzang, Nicholas J.
Bryce, Alan Haruo
McDermott, Raymond S.
Ricci, Francesco
Rowe, Julie Haewon
Zhang, Jingsong
Loehr, Andrea
Despain, Darrin
Dowson, Melanie
Golsorkhi, Tony
Chowdhury, Simon
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[20] Prediction of PARP inhibitor response and resistance utilizing a CTC phenotypic classifer in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from the NCI 9012 trial
Feng, F. Y.
Daignault-Newton, S.
Jendrisak, A.
Wang, Y.
Greene, S.
Rodriguez, A.
Lee, J.
Dugan, L.
Siddiqui, J.
Louw, J.
Johnson, C.
Twardowski, P.
Albany, C.
Stein, M.
Stadler, W. M.
Kunju, L.
Chinnaiyan, A. M.
Landers, M.
Dittamore, R.
Hussain, M.
ANNALS OF ONCOLOGY, 2016, 27

← 1 2 3 4 5 →